Literature DB >> 22513365

Predictors of survival in Chinese patients with lupus nephritis.

Z H Zheng1, L J Zhang, W X Liu, Y S Lei, G L Xing, J J Zhang, S X Quan, D Liu, D S Hu, L L Li, Z S Liu.   

Abstract

The current study was to determine the predictors of survival in 491 Chinese patients with lupus nephritis (LN). All patients were evaluated and consecutively followed up from 2003 to 2010. The female: male ratio was 9.5:1, with a median age of 31.1 ± 12 years. Forty-nine (10.0%) patients were lost to follow-up and 47 (10.3%) patients died. The overall cumulative probability of survival at 5, 10, 15 and 20 years by Kaplan-Meier analysis was 88%, 77%, 53% and 45%, respectively. The log-rank test showed that the probability of survival was significantly decreased in the late-onset patients (≥50 years) (P = 0.036), patients with hypoproteinaemia (≤35 g/l) (P = 0.014), patients with increased creatinine (≥1.5 mg/dl) (P = 0.002) and patients with massive proteinuria (≥3.5 g/24 h) (P = 0.009). However, the probability of survival was significantly higher in patients treated with hydroxychloroquine (HCQ) (P = 0.003) than those not treated with it. Based on a multivariate model, increased creatinine (hazard ratio (HR) = 2.041; P = 0.017) and proteinuria ≥3.5 g/24hours (HR=1.716; P = 0.016) were independent risk factors. Glucocorticoid (HR = 0.457; P = 0.01) and HCQ (HR=0.197; P = 0.026) were independent protective factors. Our findings suggest that renal dysfunction and massive proteinuria are independent risk factors for mortality. HCQ could improve the survival of patients with LN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22513365     DOI: 10.1177/0961203312445230

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

1.  Serum alpha-actinin antibody status in systemic lupus erythematosus and its potential in the diagnosis of lupus nephritis.

Authors:  Mansour Babaei; Zahra Rezaieyazdi; Nayereh Saadati; Massoud Saghafi; Maryam Sahebari; Bahram Naghibzadeh; Habibollah Esmaily
Journal:  Caspian J Intern Med       Date:  2016

2.  Mast cells in the kidney biopsies of pediatric patients with lupus nephritis.

Authors:  Stéfany Silva Santos; Carolina Marques Ramos; Maria Luiza Gonçalves Dos Reis Monteiro; Juliana Reis Machado; Marlene Antônia Dos Reis; Rosana Rosa Miranda Corrêa; Laura Penna Rocha
Journal:  J Bras Nefrol       Date:  2020-01-31

3.  Hsa_circ_0123190 acts as a competitive endogenous RNA to regulate APLNR expression by sponging hsa-miR-483-3p in lupus nephritis.

Authors:  Chunyi Zhang; Congcong Gao; Xueqi Di; Siwan Cui; Wenfang Liang; Wenbo Sun; Menghui Yao; Shengyun Liu; Zhaohui Zheng
Journal:  Arthritis Res Ther       Date:  2021-01-13       Impact factor: 5.156

4.  Identification of Molecular Markers Associated With the Pathophysiology and Treatment of Lupus Nephritis Based on Integrated Transcriptome Analysis.

Authors:  Menghui Yao; Congcong Gao; Chunyi Zhang; Xueqi Di; Wenfang Liang; Wenbo Sun; Qianqian Wang; Zhaohui Zheng
Journal:  Front Genet       Date:  2020-12-15       Impact factor: 4.599

5.  Single-center analysis of the inappropriate use of human albumin and nutritional support in hospitalized patients with hypoproteinemia in China.

Authors:  Jin Zhang; ZheTao Zhang; TianLu Shi
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 6.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Authors:  Alina Dima; Ciprian Jurcut; François Chasset; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-14       Impact factor: 5.346

7.  Clinical features and mortality in Chinese with lupus nephritis and neuropsychiatric lupus: A 124-patient study.

Authors:  Min Feng; Jun Lv; Sha Fu; Bo Liu; Ying Tang; Xia Wan; Peifen Liang; Yuchun Zeng; Jingao Li; Yanying Lu; Xiaomei Li; Anping Xu
Journal:  J Res Med Sci       Date:  2014-05       Impact factor: 1.852

8.  Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-κB signaling pathway in lupus nephritis mice.

Authors:  Ning Liang; Yanchun Zhong; Jie Zhou; Bihao Liu; Ruirui Lu; Yezhi Guan; Qi Wang; Chunlin Liang; Yu He; Yuan Zhou; Jianping Song; Jiuyao Zhou
Journal:  Exp Ther Med       Date:  2018-01-05       Impact factor: 2.447

Review 9.  Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis.

Authors:  Ming Tian; Xiaohong Song; Liping Dong; Xing Xin; Junwu Dong
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

10.  Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up.

Authors:  Filipa Farinha; Ruth J Pepper; Daniel G Oliveira; Thomas McDonnell; David A Isenberg; Anisur Rahman
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.046

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.